# Lilly reports greater weight loss with experimental combination, but more treatment exits

_Published Saturday, October 10, 2026 at 3:05 AM EDT · Science · Latest · Tier 2 — Notable_

![Mounjaro weight loss pen — Primary](https://assets.newatlas.com/dims4/default/2824305/2147483647/strip/true/crop/2000x1050+0+100/resize/1200x630!/quality/90/?url=https%3A%2F%2Fnewatlas-brightspot.s3.ap-southeast-2.amazonaws.com%2F66%2F62%2F41fccb6642be802bc9641937e290%2Fmounjaro-pen-combo.jpg&na.image_optimisation=0)

Eli Lilly reported that its experimental EloraTZP combination produced average weight loss of 23.3% after 48 weeks at the highest dose in a Phase 2b trial, compared with 14.8% for tirzepatide alone. The study involved 367 adults with obesity and type 2 diabetes.

The combination adds eloralintide, which mimics an appetite-regulating hormone, to tirzepatide. Gastrointestinal adverse events were more frequent with the combination; up to roughly a quarter of recipients discontinued treatment because of adverse events, versus barely 3% with tirzepatide alone.

Lilly plans Phase 3 testing with an optimized dose-escalation schedule. The findings were reported through a press release and have not appeared in a peer-reviewed publication.

## Sources

- [New Atlas: Technology-Innovation-Outdoor News](https://newatlas.com/disease/obesity/combining-mounjaro-boosts-weight-loss/)

---
Canonical: https://techandbusiness.org/newswire/Qz0VChDS7Pd_Xovgn_m_vF
Published: 2026-10-10T07:05:51.310Z
Story chronology: 2026-10-10T06:45:00.000Z
Retrieved: 2026-10-10T08:58:51.772Z
Publisher: Tech & Business (techandbusiness.org)